Position in VCEL
as of Mar 31, 2026
· filed May 7, 2026
Position Value
$61,123
-$218,473 QoQ
Shares Held
1,900
-71.1% QoQ
Ownership
0.004%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2021
10 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in VCEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026MEEDER ASSET MANAGEMENT INC holds $7,091,404 across 37 Biotechnology names. VCEL ranks #6 (0.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
6,094 | $4,708,465 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
3,424 | $1,528,950 | |
| 3 | CPRX |
Catalyst Pharmaceuticals, Inc.
|
10,392 | $257,305 | |
| 4 | BMRN |
Biomarin Pharmaceutical Inc
|
1,838 | $103,828 | |
| 5 | ADMA |
Adma Biologics, Inc.
|
9,759 | $87,928 | |
| 6 | VCEL |
Vericel Corp
This page
|
1,900 | $61,123 | |
| 7 | MNPR |
Monopar Therapeutics
|
637 | $34,901 | |
| 8 | ENTA |
Enanta Pharmaceuticals Inc
|
2,025 | $25,575 |
All Filings in VCEL
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $61,123 | 1,900 | Shares | Sole | 2026-05-07 | |
| 2025-06-30 | $279,596 | 6,571 | Shares | Sole | 2025-08-07 | |
| 2025-03-31 | $721,280 | 16,165 | Shares | Sole | 2025-05-07 | |
| 2024-12-31 | $129,422 | 2,357 | Shares | Sole | 2025-02-12 | |
| 2024-09-30 | $91,851 | 2,174 | Shares | Sole | 2024-11-07 | |
| 2022-09-30 | $603 | 26 | Shares | Defined | 2022-11-14 | |
| 2022-06-30 | $730 | 29 | Shares | Defined | 2022-08-08 | |
| 2022-03-31 | $1,337 | 35 | Shares | Defined | 2022-05-10 | |
| 2021-09-30 | $3,464 | 71 | Shares | Defined | 2021-11-08 | |
| 2021-06-30 | $1,785 | 34 | Shares | Defined | 2021-08-09 | |
| No filing history on record for this holder in this stock. | ||||||